Benzoxazines

• 

  Subject Areas on Research

  • A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. 
  • Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial. 
  • Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. 
  • Conformation guides molecular efficacy in docking screens of activated β-2 adrenergic G protein coupled receptor. 
  • Conformationally selective RNA aptamers allosterically modulate the β2-adrenoceptor. 
  • Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry. 
  • Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. 
  • Efavirenz: innocent bystander or direct nephrotoxin? 
  • Effect of HAART on Brain Organization and Function in HIV-Negative Subjects. 
  • Effects of neurotoxic destruction of descending noradrenergic pathways on cannabinoid antinociception in models of acute and tonic nociception. 
  • Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. 
  • Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability. 
  • High-frequency organization and synchrony of activity in the purkinje cell layer of the cerebellum. 
  • Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam. 
  • Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine. 
  • Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. 
  • Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. 
  • Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. 
  • Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study. 
  • Quantitative trait locus and computational mapping identifies Kcnj9 (GIRK3) as a candidate gene affecting analgesia from multiple drug classes. 
  • Risk Factors for Incident Hypertension Within 1 Year of Initiating Antiretroviral Therapy Among People with HIV. 
  • Spinal CCL2 Promotes Central Sensitization, Long-Term Potentiation, and Inflammatory Pain via CCR2: Further Insights into Molecular, Synaptic, and Cellular Mechanisms. 
  • Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity. 
  • The Relationship Between Efavirenz as Initial Antiretroviral Therapy and Suicidal Thoughts Among HIV-Infected Adults in Routine Care. 
  • The effect of inflammatory cell-derived MCP-1 loss on neuronal survival during chronic neuroinflammation. 
  • The synthetic cannabinoid WIN 55212-2 differentially modulates thigmotaxis but not spatial learning in adolescent and adult animals. 
  • Trace molecular detection via surface-enhanced Raman scattering and surface-enhanced resonance Raman scattering at a distance of 15 meters. 
  • Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats.